vimarsana.com

Page 283 - பொது மன்னிப்பு சர்வதேச ஒன்றுபட்டது News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Greece tax bureau finally unveils e-platform for property transactions

Greece tax bureau finally unveils e-platform for property transactions Wednesday, 03 March 2021 22:24 UPD:22:37 George Vitsaras / SOOC/George Vitsaras Greece is going through a lockdown due to the rising numbers of infected and diseased by the COVID-19 Novel Coronavirus infection, Athens, February 28, 2021 / Kαθολικό lockdown στην χώρα, λόγω της αύξησης των κρουσμάτων του COVID-19, Αθήνα, 28 Φεβρουαρίου, 2021 Greece s tax bureau, the now renamed and autonomous Independent Authority for Public Revenues (AADE), this week unveiled an online service that would have been unheard of in the country only several years ago, namely, remotely registering and completing property transactions. The online platform, called myProperty, allows a notary public - which in Greece is a legal school graduate that retains a registrar of contracts - to send a property sale contract to both a buyer and a seller s tax account inbox (myTaxisne

Welcome To IANS Live - NATION - SC: Cancellation of recruitment for public employment justified due to systemic fraud

A bench of Justices D.Y. Chandrachud and M.R. Shah observed that there may be situations where the nature of the irregularities may be manifold, and the number of candidates involved is of such a magnitude that it is impossible to precisely delineate or segregate the tainted from the untainted. The

Takeda to pay Ovid $196M for full rights to Phase 3-ready epilepsy drug

Takeda to pay Ovid $196M for full rights to Phase 3-ready epilepsy drug Takeda Pharmaceutical gains full rights to a small molecule that has shown promise treating seizures in several rare forms of epilepsy. Meanwhile, Ovid Therapeutics gains cash to support its pipeline of neurological disease drug candidates. Shares0 When Takeda Pharmaceutical and Ovid Therapeutics began working together four years ago, the partners aimed to share in the development of a drug with the potential to treat rare forms of epilepsy. The partners are ending the alliance, but Takeda leaves with full rights to a Phase 3 ready compound while Ovid gains $196 million to support its own pipeline of neurological disease drugs.

Whanganui Port upgrade enters phase 2 with focus on public spaces

Whanganui Port upgrade enters phase 2 with focus on public spaces 3 Mar, 2021 04:00 PM 3 minutes to read Essential work has been carried out at the port for the second phase to begin. Photo / Whanganui District Council Essential work has been carried out at the port for the second phase to begin. Photo / Whanganui District Council Whanganui Chronicle The Whanganui port revitalisation project, Te Pūwaha, has completed the first phase of work to prepare the site for upgrades and work is about to ramp up, with a focus on public spaces. Te Pūwaha is a collaboration involving community, hapū, Whanganui District Council, Horizons Regional Council, central government, Q-West Boat Builders and the Whanganui District Employment Training Trust.

Covid 19 coronavirus: Microbiologist on efficacy of deep cleans after Covid exposure

Covid 19 coronavirus: Microbiologist on efficacy of deep cleans after Covid exposure 3 Mar, 2021 04:00 PM 5 minutes to read From New Zealand s first Covid-19 case on February 28 2020 to entering another alert level 3 lockdown on February 28 2021 - here s a timeline of the milestones and setbacks we ve all endured. Video / NZ Herald From New Zealand s first Covid-19 case on February 28 2020 to entering another alert level 3 lockdown on February 28 2021 - here s a timeline of the milestones and setbacks we ve all endured. Video / NZ Herald Aimee Shaw is a business reporter focusing on retail, small businessaimee.shaw@nzherald.co.nz@AceeyShaw A microbiologist with more than 40 years experience says the term deep clean thrown around by businesses is a public pacifier and firms are not doing enough to mitigate Covid-19 transmission risks following positive case

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.